These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 19531928)

  • 1. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring.
    ; Keiser O; Tweya H; Boulle A; Braitstein P; Schecter M; Brinkhof MW; Dabis F; Tuboi S; Sprinz E; Pujades-Rodriguez M; Calmy A; Kumarasamy N; Nash D; Jahn A; MacPhail P; Lüthy R; Wood R; Egger M
    AIDS; 2009 Sep; 23(14):1867-74. PubMed ID: 19531928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
    Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
    Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
    Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
    AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profile of HIV-infected patients receiving second-line antiretroviral therapy in a resource-limited setting in Nigeria.
    Onyedum CC; Iroezindu MO; Chukwuka CJ; Anyaene CE; Obi FI; Young EE
    Trans R Soc Trop Med Hyg; 2013 Oct; 107(10):608-14. PubMed ID: 23959002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.
    Siripassorn K; Manosuthi W; Chottanapund S; Pakdee A; Sabaitae S; Prasithsirikul W; Tunthanathip P; Ruxrungtham K;
    AIDS Res Hum Retroviruses; 2010 Feb; 26(2):139-48. PubMed ID: 20156097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration.
    Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration
    Lancet HIV; 2019 Feb; 6(2):e105-e115. PubMed ID: 30723008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America.
    ; Keiser O; Anastos K; Schechter M; Balestre E; Myer L; Boulle A; Bangsberg D; Touré H; Braitstein P; Sprinz E; Nash D; Hosseinipour M; Dabis F; May M; Brinkhof MW; Egger M
    Trop Med Int Health; 2008 Jul; 13(7):870-9. PubMed ID: 18373510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa.
    Keiser O; Chi BH; Gsponer T; Boulle A; Orrell C; Phiri S; Maxwell N; Maskew M; Prozesky H; Fox MP; Westfall A; Egger M;
    AIDS; 2011 Sep; 25(14):1761-9. PubMed ID: 21681057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.
    ; Babiker A; Castro nee Green H; Compagnucci A; Fiscus S; Giaquinto C; Gibb DM; Harper L; Harrison L; Hughes M; McKinney R; Melvin A; Mofenson L; Saidi Y; Smith ME; Tudor-Williams G; Walker AS
    Lancet Infect Dis; 2011 Apr; 11(4):273-83. PubMed ID: 21288774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment limitations imposed by antiretroviral drug resistance mutations: implication for choices of first line regimens in resource-limited settings.
    Mtambo A; Chan K; Shen A; Lima V; Hogg R; Montaner J; Moore D
    HIV Med; 2012 Mar; 13(3):141-7. PubMed ID: 22107262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4 count-based failure criteria combined with viral load monitoring may trigger worse switch decisions than viral load monitoring alone.
    Hoffmann CJ; Maritz J; van Zyl GU
    Trop Med Int Health; 2016 Feb; 21(2):219-23. PubMed ID: 26584666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The causal effect of switching to second-line ART in programmes without access to routine viral load monitoring.
    Gsponer T; Petersen M; Egger M; Phiri S; Maathuis MH; Boulle A; Musondad P; Tweya H; Peter K; Chi BH; Keiser O;
    AIDS; 2012 Jan; 26(1):57-65. PubMed ID: 22089376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Research on the treatment effects and drug resistances of long-term second-line antiretroviral therapy among HIV-infected patients from Henan Province in China.
    Chen J; Zhang M; Shang M; Yang W; Wang Z; Shang H
    BMC Infect Dis; 2018 Nov; 18(1):571. PubMed ID: 30442114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch.
    Johnston V; Cohen K; Wiesner L; Morris L; Ledwaba J; Fielding KL; Charalambous S; Churchyard G; Phillips A; Grant AD
    J Infect Dis; 2014 Mar; 209(5):711-20. PubMed ID: 23943851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early antiretroviral therapy in HIV-1-infected infants, 1996-2008: treatment response and duration of first-line regimens.
    Judd A;
    AIDS; 2011 Nov; 25(18):2279-87. PubMed ID: 21971357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
    Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
    Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
    Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
    AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral Therapy.
    Suaysod R; Ngo-Giang-Huong N; Salvadori N; Cressey TR; Kanjanavanit S; Techakunakorn P; Krikajornkitti S; Srirojana S; Laomanit L; Chalermpantmetagul S; Lallemant M; Le Cœur S; McIntosh K; Traisathit P; Jourdain G
    Clin Infect Dis; 2015 Jul; 61(1):95-101. PubMed ID: 25838288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa.
    Fox MP; Cutsem GV; Giddy J; Maskew M; Keiser O; Prozesky H; Wood R; Hernán MA; Sterne JA; Egger M; Boulle A;
    J Acquir Immune Defic Syndr; 2012 Aug; 60(4):428-37. PubMed ID: 22433846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.